Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

Article  PubMed  Google Scholar 

Chen D, Wang R, Yu C, Cao F, Zhang X, Yan F, et al. FOX-A1 contributes to acquisition of chemoresistance in human lung adenocarcinoma via transactivation of SOX5. EBioMedicine. 2019;44:150–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dumitrescu RG. Epigenetic markers of early tumor development. Methods Mol Biol. 2012;863:3–14.

Article  CAS  PubMed  Google Scholar 

Kietrys AM, Kool ET. Epigenetics: a new methyl mark on messengers. Nature. 2016;530(7591):423–4.

Article  PubMed  PubMed Central  Google Scholar 

Chen Z, Qi M, Shen B, Luo G, Wu Y, Li J, et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 2019;47(5):2533–45.

Article  CAS  PubMed  Google Scholar 

Thapar R, Bacolla A, Oyeniran C, Brickner JR, Chinnam NB, Mosammaparast N, et al. RNA modifications: reversal mechanisms and cancer. Biochemistry. 2019;58(5):312–29.

Article  CAS  PubMed  Google Scholar 

Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Shi X, Huang T, Zhao X, Chen W, Gu N, et al. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48(11):6251–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Jia G. Reversible RNA Modification N(1)-methyladenosine (m(1)A) in mRNA and tRNA. Genom Proteom Bioinf. 2018;16(3):155–61.

Article  CAS  Google Scholar 

Xiang Y, Ye Y, Lou Y, Yang Y, Cai C, Zhang Z, et al. Comprehensive characterization of alternative polyadenylation in human cancer. J Natl Cancer Inst. 2018;110(4):379–89.

Article  CAS  PubMed  Google Scholar 

Nakano M, Nakajima M. Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics. Pharmacol Ther. 2018;181:13–21.

Article  CAS  PubMed  Google Scholar 

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34.

Article  CAS  PubMed  Google Scholar 

Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15(11):669–82.

Article  CAS  PubMed  Google Scholar 

Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, et al. m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. Embo j. 2020;39(20): e104514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Y, Li C, Zhang YJ, Wu ZH. Ferroptosis-Related Long Non-Coding RNA signature predicts the prognosis of Head and neck squamous cell carcinoma. Int J Biol Sci. 2021;17(3):702–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

Article  PubMed  Google Scholar 

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.

Article  PubMed  PubMed Central  Google Scholar 

Yi M, Nissley DV, McCormick F, Stephens RM. ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep. 2020;10(1):10258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan Y, Chen J, Wang J, Xu M, Zhang Y, Sun P, et al. Development and clinical validation of a novel 4-gene prognostic signature predicting survival in colorectal cancer. Front Oncol. 2020;10:595.

Article  PubMed  PubMed Central  Google Scholar 

Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.

Article  CAS  PubMed  Google Scholar 

Shulman Z, Stern-Ginossar N. The RNA modification N(6)-methyladenosine as a novel regulator of the immune system. Nat Immunol. 2020;21(5):501–12.

Article  CAS  PubMed  Google Scholar 

Faget J, Groeneveld S, Boivin G, Sankar M, Zangger N, Garcia M, et al. Neutrophils and snail orchestrate the establishment of a pro-tumor microenvironment in lung cancer. Cell Rep. 2017;21(11):3190–204.

Article  CAS  PubMed  Google Scholar 

Marshall EA, Ng KW, Kung SH, Conway EM, Martinez VD, Halvorsen EC, et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer. 2016;15(1):67.

Article  PubMed  PubMed Central  Google Scholar 

Sánchez-Alonso S, Setti-Jerez G, Arroyo M, Hernández T, Martos MI, Sánchez-Torres JM, et al. A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. J Immunother Cancer. 2020;8(2):e001187.

Article  PubMed  PubMed Central  Google Scholar 

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.

Article  CAS  PubMed  Google Scholar 

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–21.

Article  PubMed  PubMed Central  Google Scholar 

West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022;10(2):e003027.

Article  PubMed  PubMed Central  Google Scholar 

Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014;114(6):1052–68.

Article  CAS  PubMed  Google Scholar 

Jia Q, Wang J, He N, He J, Zhu B. Titin mutation associated